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The coxsackievirus B3 (CVB3) strain Nancy P establishes a persistent carrier-state infection without visible cytopathic
effect in primary human fibroblasts (HuFi H), whereas the derivative variant PD induces a complete lysis of the cell
monolayer. To define the molecular basis of this exceptional growth property, the complete genomes of both viruses were
sequenced and compared to all published sequences of CVB3. As a result, six unique amino acid substitutions in the VP1
capsid protein were observed. Via hybrid virus construction, the lytic phenotype was transferred to a nonlytic cDNA-
generated CVB3. Mapping experiments indicate that the presence of amino acid residues K78, A80, A91, and I92 in VP1 is
sufficient to induce “lytic” infections in HuFi H cells. Binding assays demonstrate that CVB3 Nancy P preferentially binds to
the human coxsackievirus-adenovirus receptor (CAR), while PD exhibits a very weak interaction with CAR but strong binding
to the decay accelerating factor (DAF). These results suggest that the mutated amino acid residues in VP1 are involved in
receptor recognition/binding. Moreover, the lytic replication of CVB3 PD and the hybrid virus in various nonpermissive rodent
cell lines indicates that cell surface molecules other than CAR and DAF may be involved in attachment of this variant to cell
surfaces. © 2000 Academic PressINTRODUCTION
The attachment of viruses to cell surface molecules is
the initial step of virus replication. Therefore, receptors
are considered to be a major prerequisite for virus host
range and tissue tropism. It was shown that a number of
viruses (e.g., human immunodeficiency virus, herpes-,
measles-, adeno-, and picornaviruses) may attach to two
or more distinct cell surface molecules (Evans and Al-
mond, 1998; Haywood, 1994). Results from studies with
monoclonal antibodies generated against HeLa Ohio cell
surface proteins of 70 kDa (RmcA) and 46 kDa (RmcB)
showed that coxsackievirus B3 (CVB3) recognizes two
different cell surface proteins (Crowell et al., 1986; Hsu et
al., 1988). RmcA blocked infection with CVB 1, 3, and 5,
while RmcB blocked the replication of all six prototype
coxsackie B viruses (CVBs). In subsequent studies, two
cellular receptors for coxsackie B viruses were identi-
fied. All six CVBs mediate infection via attachment to the
extracellular domain of the coxsackievirus-adenovirus
receptor (CAR), a cell membrane protein of unknown
function (Bergelson et al., 1997a; Wang and Bergelson,
999). Additionally, CVB1, 3, and 5 can utilize decay ac-
elerating factor (DAF/CD55) as attachment protein (Ber-
elson et al., 1995; Shafren et al., 1995). DAF is involved1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 149 3641 657202. E-mail: i6scmi@pop3.uni-jena.de.
77in regulation of complement activation and cell signaling.
This protein was also described as a receptor for echo-
viruses, enterovirus 70, and coxsackievirus A 21 (Bergel-
son et al., 1994; Karnauchow et al., 1996; Shafren et al.,
1997). In contrast to CAR, DAF seems to be insufficient to
facilitate cell entry and lytic infection of CVB. Cell lines
like Chinese hamster ovary (CHO) cells, mouse fibro-
blasts, and rhabdomyosarcoma (RD) cells, which do not
express CAR, are considered not to be susceptible to
CVBs. Transfection experiments with CHO cells revealed
that susceptibility to virus infection was achieved only
after transfection of cells with the CAR gene but not with
the DAF gene (Bergelson et al., 1997a). In addition, in-
duced expression of CAR on the surface of nonpermis-
sive human RD cells or murine 3T3 fibroblasts renders
these cell lines highly susceptible to CVB3-mediated lytic
infection (Shafren et al., 1997; Tomko et al., 1997).
Previously, Reagan et al. (1984) described a CVB3
variant which is able to induce a lytic infection of DAF-
expressing but CAR-deficient RD cells. With the present
set of data the lytic replication of this CVB3 RD variant
cannot be explained. Moreover, CVB3 also replicates in
human fibroblasts (Heim et al., 1995; Kandolf et al., 1985;
Tonew et al., 1995), which were found to be deficient of
CAR (Hidaka et al., 1999). The infection of human fetal
myocardial and pediatric myocardial fibroblasts with
CVB3 results in persistent carrier-state infection (Heim et
al., 1995; Kandolf et al., 1985), characterized by a small
0042-6822/00 $35.00
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78 SCHMIDTKE ET AL.number of productively infected cells without micro-
scopic visible cell destruction and high virus titers.
Tonew et al. (1995) demonstrated that the persistent
eplication of CVB3 in human fetal fibroblasts is both cell
ine- and virus-specific. Serial passages of the persistent
VB3 strain Nancy P in HuFi H led to the isolation of the
VB3 variant PD, which no longer persisted but de-
troyed the fibroblast monolayer completely, although its
erological specificity remained unchanged (Tonew et
l., 1996). Results from studies of virus attachment to
eLa Ohio cells and fibroblasts by immunoelectron mi-
roscopy suggest that CVB3 P and CVB3 PD may use
ifferent receptors, which may also explain the differ-
nces in their observed host cell specificities.
In an attempt to gain a better understanding of the
olecular basis of CVB3 P and PD cellular interactions,
e (1) compared the replication patterns of CVB3 vari-
nts in different cell lines, (2) determined the nucleotide
equences of these viruses, and (3) studied the role of
mino acid substitutions for the different replication pat-
erns by construction of chimeras and the binding of
VB3 to DAF and CAR.
RESULTS
ost range and cell-type specificity of CVB3 Nancy
ariants
Previous studies have demonstrated that infection of
uman fetal myocardial and pediatric myocardial fibro-
lasts with CVB3 results in a persistent “carrier state”
Heim et al., 1995; Kandolf et al., 1985). Likewise, a
persistent cell-culture infection of the carrier-state type is
induced by the CVB3 P in human fetal primary fibroblast
cells H (Tonew et al., 1995). After 13 passages of CVB3 P
in HuFi H, a CVB3 variant (designated CVB3 PD) was
selected, which is characterized by its ability to com-
pletely destroy the HuFi H cell monolayer (Tonew et al.,
1996).
To further investigate the host range and cell-type
specificity of the PD variant, its replication in certain
primary tissue cultures and cell lines of human and
rodent origin was assayed and compared to the replica-
tion pattern of other CVB3 strains (Fig. 1). These strains
were (1) the parental strain CVB3 P, which was obtained
from the Poliomyelitis Institute in Moscow, Russia; (2)
CVB3 M2, a cDNA-generated virus, which also induces a
carrier-state infection in human fetal fibroblasts (Kandolf
et al., 1985); (3) CVB3 HA, a hemagglutinating CVB3
variant; and (4) CVB3 31-1-93, a derivative of the PD
strain, which was obtained after four passages in the
murine heart (Merkle et al., 1999). Although the pheno-
ypic wild-type viruses CVB3 P and M2 are supposed to
nteract with the coxsackievirus-adenovirus receptor
CAR), the HA strain was described to preferentially bind
o the DAF receptor like the RD variant (Pasch et al.,
1999). As shown in Table 1, CVB3 PD induces lyticinfections of fetal and pediatric fibroblasts, whereas
CVB3 P, CVB3 M2, CVB3 HA, and CVB3 31-1-93 induced
persistent carrier-state infections. Cell-type specificity
and host range of CVB3 PD are enhanced since, in
addition to human cell lines (HuFi H, human pediatric
myocardial fibroblasts, MRC-5, RD), rodent cell lines
(L929, CHO-K1, and BHK-21) are also lysed by this virus.
In contrast to this observation, CVB3 P and M2 establish
persistent carrier-state infections in HuFi H, human pe-
diatric myocardial fibroblasts, and MRC5 or do not infect
these cell lines (RD, L929, CHO-K1, and BHK-21 cells).
The growth properties of CVB3 31-1-93 (a derivative of
PD obtained after four murine heart passages) (Merkle et
al., 1999) are identical to the wild-type strains, with re-
gard to persistent carrier-state infections of primary hu-
man fibroblast cells and lack of replication in rodent cell
lines. Studies of the replication pattern in CAR- and
DAF-transfected CHO cells revealed the dominant role of
CAR for infection of cells with CVB3 M2, P, and HA. In
contrast, CVB3 PD was able to productively infect
CHO-K1 cells in the absence of CAR and DAF receptor
proteins. As demonstrated in Fig. 2A, the three variants
CVB3 M2, P, and PD productively replicate in HuFi H
cells, whereas only CVB3 PD induces a considerable
cytopathic effect, which was quantified measuring the
cellular LDH activity (Fig. 2B). Double immunofluores-
cence studies (Fig. 2C) demonstrate the carrier-state
infection of HuFi H cells with CVB3 P and M2. In contrast,
CVB3-infected HuFi H cells clearly exhibit characteristics
of virus-induced cytopathic effect.
Sequence analysis of CVB3 Nancy variants
To study the molecular basis of the altered cell-type
specificity and host range, the complete genomes of
CVB3 P, CVB3 PD, CVB3 31-1-93, and the P1 region of
CVB3 HA were sequenced. The nucleotide sequences of
the virus variants were compared with published se-
quences of CVB3 Nancy strains (Chapman et al., 1994;
Klump et al., 1990; Knowlton et al., 1996; Lindberg et al.,
1987, 1992; Tracy et al., 1992) and submitted to the Gen-
Bank. Table 2 presents the amino acid polymorphisms in
the P1 genome region exhibited between 10 CVB3 vari-
ants. CVB3 P has accumulated four characteristic amino
acid substitutions in VP3 (M34T, I36T), 2Apro (S32N), and
Dpol (D226N), when compared to the sequence of CVB3
2 (Klump et al., 1990; Lindberg et al., 1992). Obviously,
hese substitutions do not result in altered phenotypic
roperties and may be considered as isolate-specific
ariations of the wild-type CVB3 Nancy sequence since
imilar variations were observed in other CVB3 Nancy
equences (Chapman et al., 1994; Tracy et al., 1992).
uring passage in HuFi H cells, two of these sites (VP3
36I, 2Apro N32S) reverted to the consensus sequence,while further amino acid substitutions accumulated in
VP2 (A34V), VP3 (F237Y), VP1 (E78K, K80A, V91A, L92I,
tically d
79ATTACHMENT OF CVB3 VARIANTS TO VARIOUS CELL LINESD152E, A223S), and 2C (E42G). These amino acid sub-
stitutions correlate with the altered cell-type specificity
and host range: although the parental wild-type virus P
induces a persistent carrier-state infection in fibroblast
cells, the PD strain completely lyses these cells. In ac-
cordance with the growth properties in fibroblast cells
and rodent cells, all these characteristic PD mutations of
the VP1 capsid protein and the 2C protein were reverted
FIG. 1. Relationships of 10 published CVB3 Nancy (Melnick and Le
generated from the infectious plasmid pCVB3-M2 and has a wild-type p
M 16572) (Lindberg et al., 1987), CVB3/20 (Acc. No. M 88483) (Tracy e
a noncardiovirulent derivative of CVB3/20 (Chapman et al., 1994). CVB3
by its RD phenotype, i.e., it infects and lyses human rhabdomyosarcom
is hemagglutinating (Acc. No. AF 231766) (Goldfield et al., 1957). CVB3
57056) (Knowlton et al., 1996). CVB3 PD is a P-derived variant, which is
is a derivative of CVB3 PD obtained after four passages in the mouse h
viruses (CVB3 Bgl-Spe, CVB3 Bgl-Sal, and CVB3 Sal-Spe) is schema
represented by circles.to the wild-type consensus sequence in variant CVB3
31-1-93 (Table 2).Chimeric virus construction
Nucleotide sequencing of the genomes of CVB3 P and
the variant PD suggest that the presence of certain
amino acid residues in the VP1–2Apro genome region
could explain the “lytic” phenotype of CVB3 PD. To prove
this hypothesis, a BglII/SpeI fragment of plasmid
pCVB3-M2 was exchanged with a reverse-transcribed
950) variants. CVB3 M2 (Acc. No. M 33854) (Klump et al., 1990) was
pe. Other virus isolates with wild-type phenotype are CVB3 L (Acc. No.
92), and CVB3 P (Acc. No. AF 231764) (Tonew et al., 1995). CVB3/0 is
CVB3/0 are also cDNA-generated viruses. CVB3 RD is characterized
; a partial sequence was published by Lindberg et al. (1992). CVB3 HA
the cDNA-generated, highly myocarditic Woodruff variant (Acc. No. U
fibroblast cells (Acc. No. AF 231765) (Tonew et al., 1995). CVB3 31-1-93
c. No. 231763) (Merkle et al., 1999). The construction of three chimeric
epicted (see also Fig. 3). Boxes indicate cloning steps. Viruses aredinko, 1
henoty
t al., 19
/20 and
a cells
H3 is
lytic in
eart (AcPCR-amplified DNA fragment of CVB3 PD (Fig. 3A). Upon
transfection of permissive GMK cells with the hybrid
“
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80 SCHMIDTKE ET AL.full-length cDNA, a viable chimeric virus was generated.
This virus chimera (designated CVB3 Bgl/Spe) had a lytic
phenotype in HuFi H cells (Figs. 3B and 3C), demonstrat-
ing that the exchanged BglII/SpeI fragment confers the
lytic” phenotype to CVB3 M2. Like the CVB3 PD strain,
his chimeric virus was able to lyse CHO-K1 cells (results
ot shown). Sequencing of the complete cDNA revealed
o substitution outside the BglII/SpeI fragment, which
may have resulted from cloning artifacts, while the nu-
cleotide sequence of the BglII/SpeI fragment of the chi-
meric virus confirmed the integrity of the PD-derived
sequences. To minimize the exchanged genome region,
two further hybrid full-length cDNAs were constructed,
one construct with a BglII/SalI fragment, the other with a
SalI/SpeI fragment (Fig. 3A). Transfection of GMK cells
with these full-length cDNAs gave rise to two viable virus
chimeras (Fig. 3B). Although CVB3 Bgl/Sal reduced the
viability of HuFi cells infected with this virus about 50%,
the other chimera CVB3 Sal/Spe did not (Fig. 3C). Infec-
tion of CHO-K1 cells was not observed with these chi-
meras (results not shown). These experiments indicate
FIG. 2. Replication pattern of CVB3 M2, P, and PD in HuFi H cells. H
f the respective virus variant. Virus replication was studied by titrat
irus-induced cell destruction was quantified by determination of lactate
B). The results represent the means 6 SD of two independent experim
in human fibroblasts was demonstrated by double immunofluorescenc
FIG. 5. Ca traces of VP1 of CVB3 Woodruff strain (left), CVB3 P (mid
to be involved in receptor recognition. The cartoons are based on the CV
a surface charge cluster of the Woodruff strain, which is constituted fr
the methyl group at the Cb of I92 to the palmitate (PLM) pocket factor (
to the canyon floor. The PD variant lacks this bulky side chain but has
T
Host Range and Type of In
Cell lines CVB3 M2 C
Human
HeLa Ohio lytic infection lytic infe
Primary fibroblasts, fetal (HuFi H) carrier-state infection carrier-s
Primary fibroblasts, pediatric
myocardial carrier-state infection carrier-s
MRC-5 carrier-state infection carrier-s
RD no infection no infec
Simian
Green monkey kidney (GMK) lytic infection lytic infe
Murine
L929 no infection no infec
Hamster
CHO-K1 no infection no infec
CHOCAR lytic infection lytic infe
CHODAF no infection no infec
BHK-21 no infection no infecthe side chains of the Woodruff variant with the respective side chains of the
Rasmol 2.6 (Roger Sayle, Glaxo Wellcome Research and Development, Stevethat the presence of the amino acid residues VP1 K78,
A80, A91, and I92 is sufficient to induce lytic infections in
HuFi H cells, whereas additional amino acids (i.e., E152
and S223) are necessary to infect and lyse CHO-K1 cells.
Binding properties of CVB3 variants
Virus-overlay protein binding assays (VOPBAs) were
performed to investigate the binding of the cDNA-gener-
ated CVB3 M2 as well as CVB3 P and CVB3 PD to the
CVB3-specific CAR and DAF receptor proteins. The VOP-
BAs presented in Fig. 4A demonstrate that infectious
virions of the cDNA-generated CVB3 M2, as well as the
CVB3 P, primarily bind to CAR (46 kDa). In contrast to
these viruses, virions of CVB3 PD preferentially recog-
nize determinants of DAF (70 kDa). In addition, CVB3 P
also bind to DAF, whereas CVB3 M2 virions recognize
this second CVB3-specific binding protein only weakly. In
these VOPBAs, none of the CVB variants bound to CAR-
negative and DAF-negative CHO-K1 cells. Although
CVB3 PD is able to infect these cells (Table 1), significant
ibroblast monolayers were infected with a multiplicity of infection of 1
he virus yield 24, 48, and 72 h p.i. (A). At the same time points, the
rogenase (LDH) release in the supernatant of infected cell monolayers
ach with two parallels. In addition, the virus-induced cytopathic effect
ing of vimentin and CVB3 (C).
d CVB3 PD (right) demonstrating sequence polymorphisms supposed
tal structure (Muckelbauer et al., 1995). The upper panel demonstrates
, E80, K85, and K230. The lower panel indicates the close contact of
ed by *1). The isopropyl side chain of V91 (indicated by *2) is exposed
yl side chain (A91) instead. The cartoons were generated by replacing
of CVB3 Nancy Variants
CVB3 Nancy variants
CVB3 PD CVB3 31-1-93 CVB3 HA
lytic infection lytic infection lytic infection
ection lytic infection carrier-state infection carrier-state infection
ection lytic infection carrier-state infection carrier-state infection
ection lytic infection carrier-state infection carrier-state infection
lytic infection no infection no infection
lytic infection lytic infection lytic infection
lytic infection no infection no infection
lytic infection no infection no infection
lytic infection lytic infection lytic infection
lytic infection no infection no infection
lytic infection no infection no infectionuman f
ion of t
dehyd
ents e
e stain
dle), an
B3 crys
om E78
indicat
a methABLE 1
fection
VB3 P
ction
tate inf
tate inf
tate inf
tion
ction
tion
tion
ction
tionP and PD variants using the MolMol 2K.1 (Koradi et al., 1996) and the
nage, UK) programs.
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82 SCHMIDTKE ET AL.interactions with CHO proteins were not detected in the
VOPBA. However, in contrast to CVB3 P, the CVB3 PD
variant is able to infect CAR- and DAF-negative CHO
cells, as demonstrated in the microtiter cell protection
assay in Fig. 4B. HeLa, CHO, CHOCAR, and CHODAF
cells were infected with the CVB3 M2, HA, P, and PD
strains in the presence or absence of CAR-specific
(RmcB) and DAF-specific (IF7) antibodies. Despite pref-
erential binding of CVB3 PD to the DAF receptor protein
of HeLa cells, infection of these cells by both viruses
could be inhibited only in the presence of CAR-specific
antibodies. Infection of CHOCAR and CHODAF cells with
CVB3 P and CVB3 PD could be slightly reduced by CAR-
and DAF-specific antibodies, respectively. However, in-
teractions of these viruses with membrane proteins of
HuFi H cells did not lead to the detection of specific
receptor proteins in the VOPBA (data not shown), most
likely as a result of the low level of functional receptor
proteins on human fibroblasts.
With regard to the expression of specific receptor
proteins on human HuFi H cells as well as HeLa and
CHO cells, the phenotype and level of CAR and DAF
receptor proteins were assessed by flow cytometry
(Fig. 4C). High levels of CAR and DAF were expressed
T
Amino Acid Polymorphisms of the
Viral
protein
aa
position
CVB3 M2
Klumpa
CVB3 L
Lindbergb
CVB3/20
Tracyc
C
Ch
VP4 16 R G R
VP2 13 A A V
144 A A A
151 Sg T S
VP3 34 M M M
36 I I I
155 I V V
178 F Y F
237 F F F
VP1 78 E E E
80 K E K
91 V V V
92 L L L
152 D D D
218 A A A
223 A A A
a Klump et al., 1990.
b Lindberg et al., 1987.
c Tracy et al., 1992.
d Chapman et al., 1994.
e Knowlton et al., 1996.
f Lindberg et al., 1992.
g Erroneously published as Thr.
h Y is also found in the revertant 31-1-93 and the HA strain.
i Unique amino acids of CVB3 are indicated in boldface type.
j I is also found in the ‘‘Woodruff’’ variant of CVB3.on human HeLa Ohio cells, whereas neither CAR nor
DAF expression was detected on hamster CHO-K1cells. Expression of the CAR protein on HuFi H cells
was right at the detection level, in contrast to a sig-
nificant number of cell-surface-expressed DAF mole-
cules. However, the level of DAF expression on HuFi H
cells was clearly lower than that detected on human
HeLa Ohio cells.
Taken together, these data suggest that the restricted
expression of CAR molecules on primary human fibro-
blasts may explain why infection of these cells by CVB3
is restricted to a carrier-state type and that the CVB3 PD
variant has nearly lost its CAR-binding property as a
result of the passages in human fibroblasts.
DISCUSSION
Previously, the CVB3 PD variant was described as
displaying exceptional growth characteristics in primary
human fibroblasts (Tonew et al., 1996). Using the immu-
nogold replica technique and infectious center assay, it
was demonstrated that the persistent strain CVB3 P and
its lytic derivative CVB3 PD clearly show different attach-
ment patterns. It was suggested that serial passages of
CVB3 P in HuFi H cells led to the selection of CVB3 PD
with different receptor specificity. The aim of this study
d Region of CVB3 Nancy Variants
d
CVB3
P
CVB3
PD
CVB3
31-1-93
CVB3
Woodruffe
CVB3
RD f
CVB3
HA
G G G G G G
A V V V A A
A A V A A A
S S S S S S
T T M M M M
T I I I I I
V V V V V V
Y Y Y Y V Y
F Yh Y F F Y
E K i E E E E
K A E E K K
V A V V V V
L I j L I L L
D E D D D D
A A V A A A
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83ATTACHMENT OF CVB3 VARIANTS TO VARIOUS CELL LINESgenerated CVB3 M2 induces a persistent carrier-state
infection in human fibroblasts (Kandolf et al., 1985; Heim
t al., 1995) and offers the possibility to construct cDNA-
enerated chimeras, it was included in this study. In
ddition, the CVB3 HA was studied since its receptor
nteractions were described recently (Powell et al., 1998;
asch et al.,1999).
Using CVB3 M2, P, PD, 31-1-93, and HA, as well as
arious human (HeLa, HuFi H, myocardial fibroblasts of
ediatric origin, MRC-5, and RD) and rodent (L929, CHO-
1, and BHK-21) cell lines, the unique replication pattern
f CVB3 PD was confirmed (Table 1). In addition, the
eplication of CVB3 PD in well-characterized CAR-nega-
ive cell lines like RD and CHO (Bergelson et al., 1998;
asch et al., 1999; Shafren et al., 1997) indicates that this
VB3 variant, in contrast to CVB3 P, M2, 31-1-93, and HA,
oes not depend only on CAR to infect cells. Results from
nfection experiments using CHOCAR and CHODAF cells
rovide further evidence that CVB3 P, M2, 31-1-93, and
A have an absolute requirement of CAR for the initiation
FIG. 3. Construction of chimeric viruses and determination of their re
RNA of CVB3 PD was reverse-transcribed and used to amplify the respe
SpeI) the capsid encoding DNA fragments of CVB3 PD were cloned into
pCVB3-M2 (A). The replication patterns of the chimeric viruses were stu
monolayers with a multiplicity of infection of 1 of the respective virus
means 6 SD virus titer (B) as well as the means 6 SD viability of cells
Reed and Muench (1938) and crystal violet staining, respectively. Da
indicated (ANOVA: **P , 0.01; ***P , 0.001).f infection in cell culture, whereas the CVB3 PD variant
oes not. These results confirm the hypothesis that dif-
n
Cerences in receptor utilization of these CVB3 variants
nfluence their host range and that CVB3 PD has ac-
uired the ability to recognize an additional cellular re-
eptor protein on CAR- and DAF-negative cells. Receptor
lteration has also been shown for other picornaviruses,
.g., the foot-and-mouth disease virus (FMDV) type O1
(Jackson et al., 1996; Neff et al., 1998) and polioviruses
Colston and Racaniello, 1995) as a result of adaptation
o cell cultures.
To study the molecular basis of the observed receptor
ariations, the complete viral genomes of CVB3 P, PD,
1-1-93, and the P1 region of HA were sequenced (Table
). The results reveal a high amino acid homology
$99.5) among these CVB3 strains. However, compared
o CVB3 P, 31-1-93, and HA as well as published CVB3
equences, several unique amino acid substitutions
ere observed in VP1 of CVB3 PD: E78K, K80A, V91A,
152E, and A223S. An additional amino acid substitu-
ion, L92I in VP1, was described for only the so-called
Woodruff” strain (Knowlton et al., 1996). Interestingly,
n patterns in HuFi H cells. For construction of hybrid viruses, genomic
enome region. After digestion with the appropriate enzymes (BglI, SalI,
rresponding DNA fragments of the infectious full-length cDNA plasmid
comparison to CVB3 P, M2, and PD after infection of human fibroblast
independent experiments, each with two parallels. At Day 6 p.i., the
ed with these viruses (C) were determined using the TCID50 assay of
stically different from those of CVB3 PD (a) or CVB3 Bgl/Spe (b) areplicatio
ctive g
the co
died in
in two
infectone of the six amino acid substitutions found in VP1 of
VB3 PD was previously described for the CVB3 RD
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84 SCHMIDTKE ET AL.variant (Lindberg et al., 1992), although both variants are
able to infect RD cells (Reagan et al., 1984). To further
tudy the question whether the amino acid alterations in
P1 present the molecular basis of the changes in at-
achment and lytic replication phenotype of CVB3 PD, the
equence coding for VP1 was transferred to the cDNA-
enerated CVB3 M2, which displays a persistent pheno-
ype in human fibroblasts and does not infect rodent cell
FIG. 4. Virus-overlay protein binding assays (VOPBAs) with CVB3 var
cytopathic effect (PD) in HuFi cells (A). Binding of 35S-labeled CVB3 strai
ells is shown. In addition, CAR- and DAF-mediated inhibition of CVB
HO-K1, CHOCAR, and CHODAF cells (B). Flow cytometry analysis of C
C). Dotted lines show autofluorescence with FITC-conjugated secon
xpression of DAF.ines. Like the CVB3 PD variant, the resulting chimera
VB3 Bgl/Spe (Fig. 3), which contains the unique amino
ccids substitutions, infects and lyses both HuFi and CHO
ells. The amino acid substitutions of chimera CVB3
gl/Sal were sufficient for lytic replication in human fi-
roblasts but not in CHO cells, suggesting species-spe-
ific differences in the expression of the unknown third
eceptor. The chimera CVB3 Sal/Spe, the mouse-adapted
VB3 31-1-93, which has reverted all amino acid replace-
ents in VP1, and CVB3 HA, have the same growth
pable of inducing a “carrier-state” persistence (M2 and P) or complete
mobilized membrane proteins of human HeLa Ohio and hamster CHO
tion was determined in microtiter cell protection assays with HeLa,
DAF expression on the surface of HeLa Ohio, CHO, and HuFi H cells
ntibodies, bold lines show expression of CAR, and fine lines showiants ca
ns to im
3 infec
AR andharacteristics as CVB3 P and M2.
Taken together, these findings indicate that growth
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85ATTACHMENT OF CVB3 VARIANTS TO VARIOUS CELL LINESproperties of CVB3 PD in various cell lines directly cor-
relate with the presence of amino acid substitutions in
the capsid protein VP1. According to the crystal structure
of the CVB3 Woodruff strain (Muckelbauer et al., 1995),
the amino acids K78, A80, and A91 in VP1, and Y237 in
VP3 of CVB3 PD are surface residues. Interestingly, the
VP1 amino acids E78, K85, E80, and K230 of the Woodruff
strain form a specific surface charge cluster, which could
be involved in receptor interaction (M. Rossmann, per-
sonal communication). As shown in Fig. 5 (upper panel)
the polymorphism detected in the VP1 region of CVB3 P
and PD led to significant changes in this surface charge
cluster, which could contribute to the observed differ-
ences in CAR and DAF binding of both variants. In addi-
tion, the amino acid I92 is located in a hydrophobic
pocket within VP1 of the Woodruff strain and in close
contact to the palmitate pocket factor (Fig. 5, lower
panel). According to Rossmann et al. (2000), rhino- and
nterovirus receptors bind to conserved residues within
he canyon. Receptor binding competes out the “pocket
actor,” subsequently leading to virus destabilization, pro-
ressive disassembly, and release of genomic RNA. The
ncoating of CVB3 variants containing I92 can be inhib-
ted by treatment with pleconaril, a WIN-like compound
inding to the hydrophobic pocket in VP1, whereas CVB3
trains with leucine or methionine residues are resistant
o pleconaril (Groarke and Pevear, 1999). From this ob-
ervation, it can be assumed that the P variant is ple-
onaril-resistant, whereas the PD variant is pleconaril-
ensitive. The lower panel of Fig. 5 shows that different
ide strains of amino acid residue 92 of CVB3 P and PD
re situated in the canyon floor. How this polymorphism
ontributes to different receptor interaction has to be
lucidated. Taken together, the changes in the surface
harge cluster as well as in the hydrophobic pocket
upport the hypothesis that the unique amino acids in
P1 of CVB3 PD are involved in specific receptor inter-
ctions.
VOPBA experiments performed to investigate the in-
eractions of CVB3 M2, P, PD with membrane protein
xtracts of HeLa Ohio, CHO-K1, and HuFi H cells re-
ealed clear differences between the tested CVB3
trains with regard to their interaction with DAF and CAR
Fig. 3A). CVB3 P and M2 show a strong CAR-binding
roperty but vary in their binding to DAF. Previously, it
as suggested that the interaction of the virus with DAF
s responsible for the hemagglutinating properties of
ertain CVB3 variants (Pasch et al., 1999; Powell et al.,
998). However, all CVB3 strains employed in this study
emagglutinate human erythrocytes 0 (data not shown),
lbeit at various amounts. This variation of the hemag-
lutinating properties possibly results from different af-
inities to DAF, which was recently described for clinical
VB3 isolates and laboratory strains (Bergelson et al.,997b). In contrast to CVB3 P and M2, the HuFi-propa-
ated CVB3 PD has almost lost its CAR-binding capacity,hich may be considered the most interesting result of
he VOPBAs presented in this study. However, CAR
eems to remain one of its attachment proteins in HeLa
nd HuFi cells because CVB3 P and PD compete for
hese cells (results not shown) and CAR-specific anti-
odies prevented the CVB3 PD-induced CPE in HeLa
ells (Fig. 4B). In addition, alternative yet unidentified cell
urface molecule(s) may be used by CVB3 PD for attach-
ent and to initiate infection in CAR- and DAF-negative
e.g., CHO-K1) cell lines. This conclusion was further
ubstantiated by testing the effect of CAR- and DAF-
pecific antibodies on the binding of CVB3 PD to CHO,
HOCAR, and CHODAF cells.
The data presented in this study underline that in vitro
daptation of CVB3 to CAR-deficient or low-level CAR-
xpressing cell lines may lead to the acquisition of
mino acid substitutions in the viral capsid proteins,
hereby allowing the use of additional binding molecules
nd extension of its cell tropism. Further studies are
resently underway to determine the impact of this re-
eptor variation for infection and pathogenesis in vivo.
MATERIALS AND METHODS
ell lines
HeLa Ohio (human cervix carcinoma; ATCC No. CCL-
), MRC-5 (human lung fibroblasts, ATCC No. CCL-171),
D (human rhabdomyosarcoma, ATCC No. CCL-136),
MK (green monkey kidney cells; Schaper & Bru¨mmer,
alzgitter, Germany), L-929 (C3H/An mouse fibroblasts,
TCC No. CCL-1), CHO-K1 cells (Chinese hamster ovary,
SZM No. ACC-110), CHODAF and CHOCAR (DAF- and
AR-transfected CHO cells) (Pasch et al., 1999), and
HK-21 cells (baby hamster kidney, ATCC No. CCL-10)
ere propagated in monolayers using Eagle’s minimal
ssential medium (EMEM; HeLa Ohio and L-929) or
ulbecco’s modified EMEM (all other cell lines) supple-
ented with 10% neonatal calf serum (NCS: HeLa Ohio)
r 10% fetal bovine serum (FBS: all other cell lines), 100
/ml penicillin, and 100 mg/ml streptomycin.
The primary human fibroblast line H (HuFi H), previ-
ously described by Tonew et al. (1995), was maintained
in EMEM with 10% NCS. Human myocardial fibroblasts
of pediatric origin were prepared without enzymatic di-
gestion from parts of myocardial tissue resected during
routine surgery of children (11 months–2 years) for Fal-
lot’s tetralogy as described by Heim et al. (1995). Cells
were propagated with Dulbecco’s modified EMEM sup-
plemented with 10% FBS.
CVB3 variants
The CVB3 strain Nancy P (CVB3 P) was kindly pro-
vided by the Institute of Poliomyelitis and Virus Enceph-
alitides (Moscow, Russia). The lytic CVB3 PD variant was
derived by serial passages of CVB3 P on HuFi H cells
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86 SCHMIDTKE ET AL.(Tonew et al., 1996). The myocarditic variant CVB3 31-
-93 was isolated by Merkle et al. (1999) after four heart
passages of CVB3 PD in outbred Han:NMRI mice. In
addition, CVB3 M2 a cDNA-generated virus obtained
after infection of HeLa Ohio cells with the infectious
plasmid pCVB3-M2 (Lindberg et al., 1992), which offers
the possibility to construct cDNA-generated chimeras,
and the hemagglutinating CVB3 HA (ATCC: VR-688),
whose binding capacity to CAR and DAF was character-
ized recently (Powell et al., 1998; Pasch et al.,1999), were
included in this study. The relationships of the virus
strains used in this study are indicated in Fig. 1. Titers of
virus stocks were determined by plaque assay on HeLa
Ohio cell monolayers as described previously (Tonew et
al., 1996).
Sequencing and cloning of CVB3 variants
For sequencing of CVB3 variants, permissive HeLa
Ohio cells or HuFi H were infected with the respective
virus and used for RNA preparation according to the
method of Chomczynski and Sacchi (1987). A 5-mg sam-
ple of the total RNA was reverse-transcribed using an
oligo(d)T20 primer. The resulting cDNA was PCR-ampli-
ied with the Expand Long Taq polymerase (Boehringer
annheim, Germany) and DNA fragments were se-
uenced, employing a set of 40 DNA primer pairs (not
hown). The P1 (capsid-encoding) genome region of
VB3 HA and the complete genomes of CVB3 P, PD, and
1-1-93 were sequenced. The GenBank accession num-
ers are: AF 231763 (CVB3 31-1-93), AF 231764 (CVB3 P),
F 231765 (CVB3 PD), and AF 231766 (CVB3 HA). Also,
he complete genome of the chimeric virus CVB3 Bgl/Spe
nd the exchanged regions of CVB3 Bgl/Sal and CVB3
al/Spe were sequenced, to show that it is identical to
2 except within the respective fragments.
For cloning of CVB3 PD sequences, PCR-amplified
ubgenomic DNA regions as well as the full-length plas-
id pCVB3-M2 (Klump et al., 1990; Lindberg et al., 1992)
ere digested with appropriate restriction enzymes
BglII, SalI, SpeI), ligated and used to transform the E. coli
train DH5a.
etermination of cell-type specificity of CVB3 variants
To determine the cell-type specificity of CVB3 variants,
t least three virus passages were performed in various
uman, simian, and rodent cell lines. During the first
assage, cell monolayers were infected with a multiplic-
ty of infection (m.o.i.) of 1 plaque-forming unit/cell of the
espective CVB3 variant. At 1, 24, 48, and 72 h (Fig. 1) or
t Day 3 (Table 1) postinoculation (p.i.) 50 ml of culture
upernatants of CVB3-infected cells were harvested and
ubsequently used for titration of virus yield by estima-
ion of 50% endpoints (Reed and Muench, 1938) on sus-
eptible HeLa Ohio cells. Furthermore, at Day 3 p.i., 50 ml
f the supernatant of CVB3-infected cells was transferredo fresh cell monolayers to perform the next virus pas-
age. In addition, the virus-induced destruction of cells
as quantified by determination of lactate dehydroge-
ase (LDH) release in the supernatant of infected cell
onolayers (Sigma, Deisenhofen, Germany) or crystal
iolet (KV) staining of the cell monolayers (Schmidtke et
l., 1998). The KV uptake assay is based on the quanti-
ication of optical density (OD) at 450/630 nm with a
tandard microplate photometer after dye elution. The
etermined OD was correlated with the degree of cyto-
athic effect (CPE).
Three different patterns of virus infection were ob-
erved: (1) no infection (no increases in virus titers; no
PE); (2) “carrier-state” persistence (increases in virus
iters of 102- to 104-fold after the first passage, which did
not decrease during the next passages; no microscopic
visible CPE); and (3) lytic infection (increases in virus
titers of 104- to 105-fold after the first passage, which did
not decrease during the next passages; complete CPE).
Double immunofluorescence
For characterization of human fibroblast cultures, cells
were fixed with a Formalin/methanol solution and incu-
bated with a monoclonal antibody against vimentin, a
cytoskeleton protein (Dianova, Hamburg, Germany). After
rinsing with PBS, the secondary Cy2-conjugated goat
anti-mouse antibody (Dianova) was applied for visualiza-
tion. Following three further washing steps with PBS,
CVB3 staining of infected cells was carried out using a
rabbit hyperimmune serum against CVB3 Nancy P and a
Cy3-conjugated goat anti-rabbit antibody (Dianova).
FACS analysis
Analysis of CAR and DAF expression on human HeLa
Ohio, HuFi H, and CHO-K1 cells was performed by flow
cytometry with a FACSCalibur (Becton Dickinson Bio-
sciences, San Jose, CA). For detection of cell-surface-
expressed CAR proteins, cells were stained at 4°C for 30
min with CAR-specific RmcB antibodies (dilution 1:150),
followed by a 30-min incubation with FITC-conjugated
anti-mouse IgG. The CAR-specific RmcB antibodies were
kindly provided by J. Bergelson (Philadelphia, PA). DAF
expression was monitored by direct staining of cells (30
min) with FITC-conjugated anti-CD55 antibody (CCBL512;
Dianova). Controls were incubated with secondary anti-
bodies only.
Virus-overlay protein binding assay (VOPBA)
The virus-overlay protein binding assay was per-
formed as previously described (Pasch et al., 1999).
Briefly, 50–150 mg of octyl glucoside-solubilized mem-
brane proteins were separated by sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis (SDS–PAGE)
and electroblotted on polyvinylidene difluoride (PVDF)
membranes. The filters were exposed to 35S-labeled vi-
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87ATTACHMENT OF CVB3 VARIANTS TO VARIOUS CELL LINESruses (300,000 cpm each) for 24 h and washed with
PBS/0.05% Tween; membrane-bound radioactivity was
detected by autoradiography.
Antibody-mediated inhibition of CVB3 infection
The inhibitory effect of anti-CAR (RmcB) and anti-DAF
(IF7) antibodies on CVB3 infections of various cell lines
was determined in microtiter cell protection assays.
Cells were reincubated for 30 min at RT with RmcB or IF7
(1:100 dilution of ascites fluids) or DMEM without anti-
bodies, followed by inoculation with the CVB3 variants.
The presence of antibodies in the culture medium was
maintained throughout the experiment. Reactions were
stopped 24 h p.i. and surviving cells were stained with
crystal violet.
Statistical analysis
The ANOVA was used to analyze the differences be-
tween virus strains in the induction of cytopathic effect.
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